Acknowledging advances in early detection of multiple sclerosis (MS), the Paralyzed Veterans of America (PVA) is broadening its membership and inviting all veterans with the progressive neurodegenerative disorder to join the nonprofit organization. Now, all veterans with MS are eligible for PVA membership and the same support available to…
ALS
A nuclear protein called heterogeneous nuclear ribonucleoprotein A1 or hnRNP A1 — abnormally found outside the nucleus in people with neurodegenerative diseases such as multiple sclerosis (MS) — is essential for nerve cell function and survival. Those are the findings of a new study, by Canadian researchers, of nerve…
Scientists have created myelin-producing cells, called oligodendrocytes, from pluripotent stem cells derived from patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) in just three weeks. They also demonstrated these lab-made oligodendrocytes were able to produce myelin — the fatty substance that normally wraps around neurons’…
The Phase 2 clinical trial testing BrainStorm Cell Therapeutic’s investigational NurOwn therapy for progressive multiple sclerosis (MS) has added a third clinical site, the company announced. The trial (NCT03799718) now will enroll patients at the Keck School of Medicine of The University of Southern California (USC), and its academic…
BrainStorm Cell Therapeutics announced the Cleveland Clinic is the first clinical site contracted in the United States for the Phase 2 multi-center study evaluating the company’s NurOwn mesenchymal stem cell (MSC) therapy in individuals with progressive multiple sclerosis (MS). “We are very excited to announce The Mellen Center for…
Denali Therapeutics and Sanofi will collaborate to develop a compound called DNL747 that may treat multiple sclerosis (MS) and other neurodegenerative disorders. The companies will also jointly work on the development of a separate possible therapy, DNL758, for systemic inflammatory diseases such as rheumatoid arthritis and psoriasis. Both DNL747 and DNL758…
Multiple sclerosis patients are among those with debilitating diseases who are most satisfied with their healthcare, two surveys indicate. Others who are satisfied include people with amyotrophic lateral sclerosis and Parkinson’s, according to the questionnaire-based PatientsLikeMe research. In contrast, people with fibromyalgia, post-traumatic stress disorder (PTSD) and major depressive disorder…
Topline results of an exploratory Phase 2 clinical trial revealed that Flex Pharma‘s treatment candidate FLX-787 improves muscle cramps, spasms and muscle stiffness in patients with multiple sclerosis (MS). The double-blinded trial, conducted in Australia, evaluated an oral dose of 19 mg FLX-787, taken twice daily in liquid…
Flex Pharma said it plans to prioritize developing its clinical programs in neurological diseases, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and peripheral neuropathies like Charcot-Marie Tooth (CMT). One or two proof-of-concept, Phase 2 clinical trials are planned for this year in the United States to evaluate Flex Pharma’s…
Paralyzed Veterans of America recently held its annual health conference, called 2016 Summit + EXPO, focused on the latest research and discoveries in patient care for diseases that span multiple sclerosis and spinal cord injury or disease to  amyotrophic lateral sclerosis. This year was the sixth such summit, held Aug. 30–Sept. 1 in Orlando, Florida,…